Open Access

Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis

  • Authors:
    • Wei Wei
    • Ruihao Peng
    • Lishan Kuang
    • Changyuan Xu
    • Yan Cao
    • Luqing Zeng
    • Ximei Wen
    • Qianqian Qin
    • Cuncai Zheng
    • Wenyun Li
    • Sujian Xia
  • View Affiliations

  • Published online on: November 14, 2019     https://doi.org/10.3892/ol.2019.11094
  • Pages: 261-270
  • Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Clinical trials have previously assessed various therapies for renal cell carcinoma (RCC); however, there is currently a lack of direct comparisons between these therapies. The present study identified published studies on RCC through Web of Science, PubMed, EMBASE, Cochrane Library of Controlled Trials and Clinical trials.gov that were written in the English language and published by February 2019. The data were selected and extracted independently by two reviewers. Standard pair‑wise meta‑analyses were performed using Stata. Network meta‑analyses were subsequently performed using WinBUGS (version 1.4.3). The primary outcome of the present study was progression‑free survival (PFS). Secondary outcomes included overall survival (OS), objective response rate (ORR) and adverse events of various targeted therapies. The results were presented as cumulative odds ratio, hazard ratio, corresponding 95% confidence interval and the surface under the cumulative ranking curve, which was used to rank the probabilities and outcome of each treatment in RCC. A total of 31 eligible publications for 18 randomized controlled trials consisting of 11,498 participants were included in the present study. The network meta‑analyses revealed that a combination of lenvantinib and everolimus ranked first out of 16 treatments in terms of PFS, OS and ORR (probability of 54.0, 53.4 and 61.0%, respectively).
View Figures
View References

Related Articles

Journal Cover

January 2020
Volume 19 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Wei, W., Peng, R., Kuang, L., Xu, C., Cao, Y., Zeng, L. ... Xia, S. (2020). Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis. Oncology Letters, 19, 261-270. https://doi.org/10.3892/ol.2019.11094
MLA
Wei, W., Peng, R., Kuang, L., Xu, C., Cao, Y., Zeng, L., Wen, X., Qin, Q., Zheng, C., Li, W., Xia, S."Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis". Oncology Letters 19.1 (2020): 261-270.
Chicago
Wei, W., Peng, R., Kuang, L., Xu, C., Cao, Y., Zeng, L., Wen, X., Qin, Q., Zheng, C., Li, W., Xia, S."Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis". Oncology Letters 19, no. 1 (2020): 261-270. https://doi.org/10.3892/ol.2019.11094